Abstract:Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease that occurs due to increased fibrosis of lung tissue in response to chronic injury of the epithelium. Therapeutic options for IPF remain limited as current therapies only function to decrease disease progression. Recently, extracellular vesicles (EVs), including exosomes and microvesicles, have been recognized as paracrine communicators through the component cargo. The population of cell-specific microRNAs and proteins present in EVs can regulate gene expressions of recipient cells, resulting in modulation of biological activities. EV cargoes reflect cell types and their physiological and pathological status of donor cells. Many current researches have highlighted the functions of EVs on the epithelial phenotype and fibroproliferative response in the pathogenesis of IPF. Furthermore, some native EVs could be used as a cell-free therapeutic approach for IPF as vehicles for drug delivery, given their intrinsic biocompatibility and specific target activity. EV-based therapies have been proposed as a new potential alternative to cell-based approaches. The advantage is that EVs, depending on their source, may be less immunogenic than their parental cells, likely due to a lower abundance of transmembrane proteins such as major histocompatibility complex (MHC) proteins on the surface. In the last decade, mesenchymal stem cell (MSC)-derived EVs have been rapidly developed as therapeutic products ready for clinical trials against various diseases. Considering EV functional complexity and heterogeneity, there is an urgent need to establish refined systemic standards for manufacturing processes and regulatory requirements of these medicines. This review highlights the EV-mediated cellular crosstalk involved in IPF pathogenesis and discusses the potential for EV-based therapeutics as a novel treatment modality for IPF.

Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis

Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis

Current and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review)

Therapeutic Potential of Exosomes in Pulmonary Fibrosis.

Exosomes As Mediators and Biomarkers in Fibrosis

The novel insights of epithelial-derived exosomes in various fibrotic diseases

Pulmonary fibrosis: pathogenesis and therapeutic strategies

The Extracellular Matrix Enriched with Exosomes for the Treatment on Pulmonary Fibrosis in Mice

Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics

Exosomes on the development and progression of renal fibrosis

The Emerging Role of Extracellular Vesicles from Mesenchymal Stem Cells and Macrophages in Pulmonary Fibrosis: Insights into miRNA Delivery

Late Breaking Abstract - Evaluating the clinical potential of inhalation of umbilical cord mesenchymal stem cell (UC-MSC) exosomes in pulmonary fibrosis (PF) treatment.

Exosomes：carriers of pro-fibrotic signals and therapeutic targets in fibrosis.

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery

Research progress of exosome in the pathogenesis, diagnosis and treatment of chronic obstructive pulmonary disease

Stem cell-based therapy for pulmonary fibrosis

Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications

Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives

Discovering the role of microRNAs and exosomal microRNAs in chest and pulmonary diseases: a spotlight on chronic obstructive pulmonary disease

The role of exosomes from BALF in lung disease

Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects